Trial Profile
A Phase 2a Proof-of-Mechanism, Open-Label Study to Determine the Effect of ACH-0144471 on C3 Levels in Participants With Low C3 Levels Due to Either C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Danicopan (Primary)
- Indications Membranoproliferative glomerulonephritis
- Focus Biomarker; Therapeutic Use
- Sponsors Alexion AstraZeneca Rare Disease
- 19 Aug 2019 Status changed from recruiting to completed.
- 11 Apr 2019 This trial has been completed in Belgium, according to European Clinical Trials Database.
- 07 Mar 2019 According to a Achillion media release, the compnay plans to present data from its phase II clinical trials of Paroxysmal nocturnal haemoglobinuria and C3 glomerulopathy or membranoproliferative glomerulonephritis to FDA in the fourth quarter of 2019.